[PRESS RELEASE 16 January 2018] Researchers at Karolinska Institutet report that cholesterol metabolites cause specific immune cells in the large intestine to move, which lies behind the formation of the immune system's important lymphoid tissue in the intestine. The study, published in the journal Immunity, paves the way for a new possible treatment for patients with inflammatory bowel disease.
Inflammatory bowel disease is a common and severe disease that has no cure. Normally, the immune cells of the gut accumulate and communicate with each other in the lymphoid tissue. But, for those who have autoimmune inflammatory bowel disease, such as ulcerative colitis, the lymphoid tissue can react to the body's own cells and cause chronic inflammation.
Hitherto, it has not been known which signals control the formation of the lymphoid tissue in the large intestine. But, now scientists at Karolinska Institutet have discovered that cholesterol metabolites, called oxysterols, stimulate specific immune cells in the large intestine, called innate lymphoid cells (ILCs), to form lymphoid tissue in both health and in disease.
“We have discovered that ILCs use a surface protein called GPR183 to sense the oxysterols, which attracts ILCs to specific sites in the large intestine where lymphoid tissue is formed,” says Tim Willinger, researcher at Karolinska Institutet’s Department of Medicine in Huddinge, who has led the study.
“Our findings are relevant to humans because inflammatory lymphoid tissue contributes to tissue damage in inflammatory bowel disease. We have discovered that patients with ulcerative colitis have higher levels of oxysterol-producing enzymes than healthy controls. The results indicate that oxysterols and GPR183 are involved in ulcerative colitis,” he says.
One way to treat inflammatory bowel disease could, therefore, be to attempt to inhibit GPR183 or oxysterol production.
“This treatment option is attractive, because GPR183 belongs to a group of molecules that are excellent targets for drug treatment,” says Dr Willinger.
The study was financed by a Junior Investigator Research Grant from the Center for Innovative Medicine (CIMED) from Karolinska Institutet/Stockholm County Council.
Publication: ”Oxysterol sensing through the receptor GPR183 promotes the lymphoid tissue-inducing function of innate lymphoid cells and colonic inflammation”. Johanna Emgård, Hana Kammoun, Bethania García-Cassani, Julie Chesné, Sara M. Parigi, Jean-Marie Jacob, Hung-Wei Cheng, Elza Evren, Srustidhar Das, Paulo Czarnewski, Natalie Sleiers, Felipe Melo-Gonzalez, Egle Kvedaraite, Mattias Svensson, Elke Scandella, Matthew R. Hepworth, Samuel Huber, Burkhard Ludewig, Lucie Peduto, Eduardo J. Villablanca, Henrique Veiga-Fernandes, João P. Pereira, Richard A. Flavell, Tim Willinger. Immunity, online 16 January 2018.
For more information, please contact:
Tim Willinger, Senior Researcher
Department of Medicine, Huddinge, Karolinska Institutet
E-mail: [email protected]
Phone (Press Office): +46 8 524 860 77
Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Powered by WPeMatico